Intronbio Transfers Sponsorship of SAL200 Phase 2 Clinical Trial to US FDA

[Asia Economy Reporter Hyungsoo Park] Intron Bio, a biopharmaceutical company specializing in new drug development (CEO Kyungwon Yoon), announced on the 23rd that it has completed the FDA IND sponsorship transfer process for the Phase 2 clinical trial of SAL200 in the United States.

Intron Bio has finalized the acquisition of the FDA IND sponsor rights for the superbug biopharmaceutical SAL200 from Lysovant. From now on, Intron Bio holds all rights related to the clinical trials of SAL200 in the U.S. Intron Bio plans to proceed with the clinical trials through new technology licensing (L/O) partnerships to be established.

Kyungwon Yoon, CEO of Intron Bio, stated, "We are in the process of acquiring all rights and clinical data related to SAL200 from Lysovant," adding, "The process is progressing smoothly under a friendly cooperative relationship."

He continued, "SAL200 is a drug that has entered the U.S. clinical trial phase with FDA IND approval," and "its technical maturity has improved compared to when it was first licensed out in 2018." Furthermore, he emphasized, "It is a drug that has achieved significant technical progress," and "as an innovative drug to solve the antibiotic-resistant bacteria problem, the value of SAL200 has increased even more."

CEO Yoon said, "The issue of antibiotic-resistant bacteria continues to be seriously warned," and "the necessity of SAL200 as a powerful innovative new drug candidate capable of solving this problem will grow even greater."

This content was produced with the assistance of AI translation services.